{"schema_version":"secwatch.filing_event.v1","accession":"0001730463-25-000064","form_type":"8-K","ticker":"AUTL","cik":"0001730463","company_name":"Autolus Therapeutics plc","filed_at":"2025-08-12T23:59:59+00:00","discovered_at":"2026-05-14T18:02:44.828521+00:00","generated_at":"2026-05-17T14:41:50.134056+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Autolus reports Q2 AUCATZYL revenue $20.9M; EU/UK approvals secured but Germany launch on hold","bullets":["Net product revenue $20.9M in Q2, $29.9M H1 2025; 46 U.S. centers activated, >90% medical lives covered.","UK MHRA (Apr 25) and EC (Jul 17) conditional approvals granted for AUCATZYL in r/r B-ALL.","NICE preliminary ACD recommended against funding; EU launch paused, no sales expected in 2025-2026.","Cash $454.3M (Jun 30 vs $588.0M Dec 31); net loss $47.9M (Q2 2025) vs $58.3M (Q2 2024).","Pipeline: obe-cel Phase 2 LN trial and Phase 1 MS trial first patient dosing by year-end 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001730463-25-000064","json":"https://secwatch.observer/filing/0001730463-25-000064.json","markdown":"https://secwatch.observer/filing/0001730463-25-000064.md","text":"https://secwatch.observer/filing/0001730463-25-000064.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1730463/000173046325000064/0001730463-25-000064-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1730463/000173046325000064/autl-20250812.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T14:41:50.134056+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}